IGHE and cancer: Pre-clinical studies of the first anti-cancer IgE, MOv18 IgE (targeting the cancer antigen folate receptor alpha, FRα) have now been translated to a first-in-human, first-in-class Phase I clinical trial (NCT02546921)27.